Evaluating Value and Risk in Biotech Platforms

What challenges do first-time founders or tech founders encounter when building companies in the bio space, and how do they differ from traditional tech companies? In this hallway-style conversation episode of the a16z Podcast (originally recorded as a video), a16z bio team general partners Vijay Pande and Jorge Conde, with Jeff Low discuss the mindset shifts involved in building bio (particularly therapeutics) companies. They cover everything from different paths to market and different partnerships (including pharma) to different timelines and milestones for validating the product and business itself. But how do we get to a common language that bridges the worlds of tech and bio?